Angiotensin-converting enzyme (ACE) inhibitors were found to be independently associated with reducing all-cause mortality in ...

Pulmospheres, three dimensional multicellular spheroids composed of lung cells from individual patients, were shown to be effective in predicting the efficacy of medications for idiopathic pulmonary ...

Designation highlights significant unmet medical needAUSTIN, Texas, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ...

Among patients with idiopathic pulmonary fibrosis, the risk for all-cause mortality was significantly lower with vs. without angiotensin-converting enzyme inhibitor use started within 5 years before ...

CAMBRIDGE, Mass., June 3, 2025 /PRNewswire/ -- Artificial intelligence (AI) is rapidly transforming the pharmaceutical industry, reshaping the landscape from target identification to personalized ...

Real-world EHR data suggest ACE inhibitor use is independently associated with lower all-cause mortality in idiopathic pulmonary fibrosis, while no similar survival association was observed in COPD.

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...

Opioid agonist/antagonist has a big impact in phase IIb trial ...

Learn to manage chronic fatigue from IPF with exercise, nutrition, sleep hygiene, and energy-saving strategies.

It might start with a shortness of breath that’s easily dismissed as getting older or needing more exercise. But for the nearly 3 million patients with idiopathic pulmonary fibrosis (IPF), this subtle ...